Forced expression of alpha-myosin heavy chain in the rabbit ventricle results in cardioprotection under cardiomyopathic conditions.
about
Opposing roles of FoxP1 and Nfat3 in transcriptional control of cardiomyocyte hypertrophyFunctional consequence of mutation in rat cardiac troponin T is affected differently by myosin heavy chain isoformsSmall and large animal models in cardiac contraction research: advantages and disadvantagesAlpha1A-adrenergic receptor-directed autoimmunity induces left ventricular damage and diastolic dysfunction in rats.Ca2+-independent positive molecular inotropy for failing rabbit and human cardiac muscle by alpha-myosin motor gene transfer.Effects of myosin heavy chain manipulation in experimental heart failure.Chromatin regulation by Brg1 underlies heart muscle development and diseaseChromatin remodeling in cardiovascular development and physiology.Altered myofilament stoichiometry in response to heart failure in a cardioprotective α-myosin heavy chain transgenic rabbit modelIdentification of functional differences between recombinant human α and β cardiac myosin motors.Development of dilated cardiomyopathy in Bmal1-deficient miceRBFox1-mediated RNA splicing regulates cardiac hypertrophy and heart failureTransgenic rabbit models for studying human cardiovascular diseases.Phospholamban overexpression in transgenic rabbitsModerate intensity, but not high intensity, treadmill exercise training alters power output properties in myocardium from aged ratsFactors controlling cardiac myosin-isoform shift during hypertrophy and heart failureErratum to: Identification of functional differences between recombinant human α and β cardiac myosin motors.Designing heart performance by gene transfer.Increase in cardiac myosin heavy-chain (MyHC) alpha protein isoform in hibernating ground squirrels, with echocardiographic visualization of ventricular wall hypertrophy and prolonged contractionEffects of cardiac myosin isoform variation on myofilament function and crossbridge kinetics in transgenic rabbitsTargeting histone deacetylases for heart failure.Kidney and heart interactions during cardiorenal syndrome: a molecular and clinical pathogenic framework.Individual evaluation of cardiac marker expression and self-beating during cardiac differentiation of P19CL6 cells on different culture substrates.The myosin activator omecamtiv mecarbil: a promising new inotropic agent.TRPC6 fulfills a calcineurin signaling circuit during pathologic cardiac remodeling.On mice, rabbits, and human heart failure.Activation of SIRT1, a class III histone deacetylase, contributes to fructose feeding-mediated induction of the alpha-myosin heavy chain expression.Complete Characterization of Cardiac Myosin Heavy Chain (223 kDa) Enabled by Size-Exclusion Chromatography and Middle-Down Mass Spectrometry.Melatonin protects against the pathological cardiac hypertrophy induced by transverse aortic constriction through activating PGC-1β: In vivo and in vitro studies.MR tagging demonstrates quantitative differences in regional ventricular wall motion in mice, rats, and men.Impaired myocardial performance in a normotensive rat model of intrauterine growth restriction.The wide utility of rabbits as models of human diseases.
P2860
Q28579882-80DA1250-3372-4445-A8C7-182B28727AADQ28580787-4C52DA89-AB41-4544-8B9B-DB4C931D3891Q28658055-8F40CB2D-C432-4AFF-B4F8-D8862F012D71Q33535920-BC18D982-D78C-42E4-A389-99E1FEFEBAE8Q33724399-AACF50C8-AE76-4560-8FEA-632CADD9F655Q33787982-343F4565-9B60-41C7-81AB-4D328B705856Q33969388-A09E7312-910B-4668-B964-7B1D19AFAB42Q34814306-A4B6FE81-DEEF-4A0B-9EC2-83DC77DDD972Q35071250-B7E42AC3-FBDD-4E98-8259-1C806D979818Q36032815-04CD3016-E741-4255-83C4-9ADD89F270E7Q36176071-D620BB6D-0458-445F-94C3-A5DF8D7D25BAQ36430719-0261BB68-7B3C-4FD7-84B9-2E6843AABE3EQ36481289-2745317C-FB42-4C4C-9DF2-189EF58A1768Q36628719-1FB05839-0628-4F8D-873F-9B998488428AQ36796219-50F28C2A-5A29-4052-98D1-E1B53D6DEEB9Q36919409-B4B2C689-CED1-4127-90DF-D613B8F2B8A4Q36937943-ADE60225-D3C0-4CCE-A65D-11BD5154FD46Q37299072-E8927D9E-772D-4CB5-AA0B-18C40724EEADQ37364257-6BED6359-C9C3-4455-A950-E59535A3E748Q37382700-DBEADC98-D88E-4FF3-8B71-F4A26985EF24Q37494673-4E4DF023-0F8F-441D-8C1B-E15A3FE7B33FQ37907323-B24C1F98-F1AF-4381-B98E-47450FC566E4Q38726132-E74CAD83-86EA-41BC-9FC4-263D97710CEDQ38870685-33CA3231-CA49-4672-9BA7-8182E354679BQ39076684-983B5BB9-9723-49C1-AAA2-3B6FDB30E8E7Q42623343-7FEB666F-3089-409A-8DDB-DCB5F426DCD5Q46810326-5C05D1EA-7FE6-4B5F-98F4-C82B974E5508Q47224273-8F8A31F5-7383-4891-AFC9-C1090C94955BQ47924477-5FE71967-9A18-425E-8065-63B285630D3CQ51187686-95E58ECB-E004-41D5-A68C-143C2AA27853Q54372536-F300654D-40F1-4DCE-9E1D-82050E021811Q55250836-9421769F-8A61-4F36-B34A-3017A1039414
P2860
Forced expression of alpha-myosin heavy chain in the rabbit ventricle results in cardioprotection under cardiomyopathic conditions.
description
2005 nî lūn-bûn
@nan
2005 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Forced expression of alpha-myo ...... er cardiomyopathic conditions.
@ast
Forced expression of alpha-myo ...... er cardiomyopathic conditions.
@en
Forced expression of alpha-myo ...... er cardiomyopathic conditions.
@nl
type
label
Forced expression of alpha-myo ...... er cardiomyopathic conditions.
@ast
Forced expression of alpha-myo ...... er cardiomyopathic conditions.
@en
Forced expression of alpha-myo ...... er cardiomyopathic conditions.
@nl
prefLabel
Forced expression of alpha-myo ...... er cardiomyopathic conditions.
@ast
Forced expression of alpha-myo ...... er cardiomyopathic conditions.
@en
Forced expression of alpha-myo ...... er cardiomyopathic conditions.
@nl
P2093
P2860
P1433
P1476
Forced expression of alpha-myo ...... er cardiomyopathic conditions.
@en
P2093
Carmen Quatman
Fred Jones
James Gulick
Jeanne James
Jeffrey Robbins
Lisa Martin
Maike Krenz
Raisa Klevitsky
P2860
P304
P356
10.1161/01.CIR.0000164233.09448.B1
P407
P577
2005-05-02T00:00:00Z